Global Cancer Biomarkers Market to Grow at a CAGR of 14.3% During 2024-2032, Driven by Rising Cancer Prevalence

The cancer biomarkers market size is propelled by several key drivers such as the growing incidence of cancer worldwide, increasing awareness and early detection efforts, advancements in biomarker discovery technologies, and the growing focus on personalized medicine. Additionally, the expansion of targeted therapies and the integration of biomarkers in drug development and clinical trials amplify market growth.

In May 2023 , Fujitsu Limited, Kyoto University, and Chordia Therapeutics, Inc. announced the start of AI field trials aimed at identifying biomarkers for cancer drug development, using Fujitsu's AI causal discovery technology. This collaboration intends to enhance the efficiency of clinical trials and the development of new cancer treatments by analyzing genomic information from Kyoto University's platform and applying advanced AI.

The project focuses on discovering biomarkers for patient stratification in treatments targeting RNA regulatory stress, a venture that began in May 2018. This effort underlines the commitment to personalized cancer treatment, leveraging cutting-edge technology to improve patient outcomes and accelerate the discovery and development of new drugs.

Government initiatives and funding for cancer research have also played a pivotal role in supporting the development and adoption of biomarker-based tests. Furthermore, the collaboration between academic institutions, research laboratories, and companies in the biopharmaceutical sector is fostering a conducive environment for the discovery of novel biomarkers and the development of biomarker-based tests and therapies.

In September 2023 , the Breast Cancer Research Foundation (BCRF) committed USD 60.2 million to fund over 250 scientists in 14 countries for breast cancer research in 2023-2024. A significant portion of this investment is directed toward advancing the understanding of cancer biomarkers, crucial for early detection, predicting treatment responses, and developing new targeted therapies.

This focus on biomarkers is part of BCRF's broader research efforts spanning prevention, treatment, and improving quality of life for breast cancer patients. As the largest private funder of breast cancer research globally, BCRF's initiatives are pivotal in driving progress against the disease.

The cancer biomarkers market demand is witnessing substantial growth, driven by an increasing recognition of their critical role in the early detection, diagnosis, and management of cancer. Cancer biomarkers offer the potential for personalized treatment plans, enabling healthcare providers to tailor therapies based on the specific genetic makeup of both the patient and the tumor, thus improving treatment outcomes and reducing side effects.

Technological advancements in genomics and proteomics have dramatically enhanced the ability to identify and validate new biomarkers, making these tools more accessible and cost-effective for clinical use. Moreover, the growing prevalence of cancer globally, coupled with heightened awareness and screening programs, is driving the demand for biomarkers in oncology diagnostics and therapeutic monitoring.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Analysis by Type, Cancer Type, Applications, Profiling Technologies, End Users, and Region

• In terms of biomarker types, the market comprises protein biomarkers, genetic biomarkers, and other emerging biomarkers.

• Cancer biomarkers are applied across various cancer types including lung cancer, breast cancer, leukemia, melanoma, colorectal cancer, prostate cancer, and others, with specific biomarkers tailored to each cancer's characteristics.

• The cancer biomarkers market segmentation is also based on applications, which includes prognostics, diagnostics, research and development, and other emerging uses.

• Profiling technologies utilized in cancer biomarker detection encompass omics, imaging, immunoassay, bioinformatics, and other advanced methodologies.

• End-users of cancer biomarker products and services include pharmaceuticals and biotechnology companies, diagnostics and research laboratories, hospitals, and other healthcare entities.

• Geographically, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, each region offering unique opportunities and challenges in cancer biomarker adoption and development.

Key Findings of the Report

• The cancer biomarkers market analysis highlights a robust growth trajectory for the cancer biomarkers market, propelled by the rising global incidence of cancer and the increasing demand for early detection and personalized medicine. This growth is further supported by advancements in technologies for biomarker discovery and validation, which are making these tools more accessible and cost-effective for clinical application.

• A key finding is the pivotal role of technological advancements in genomics, proteomics, and bioinformatics in driving the market. These innovations enhance the precision and efficiency of cancer biomarker detection, facilitating the development of targeted therapies and contributing to the market's expansion.

• The report identifies a wide range of applications for cancer biomarkers, including risk assessment, early detection, diagnosis, prognosis, and monitoring of therapeutic response. This diversity in application underscores the versatility of biomarkers in improving cancer care across various stages of the disease.

• Despite the market's growth, the report points out significant challenges related to regulatory approval processes and reimbursement policies for biomarker-based tests. These challenges can impact the market's dynamics by influencing the adoption rate of new biomarker tests and therapies.

• Another critical insight is the importance of collaborative efforts among academic institutions, research laboratories, and pharmaceutical companies in advancing biomarker research and development. Such collaborations are crucial for overcoming technical and financial barriers, leading to the discovery of novel biomarkers and the development of innovative diagnostic and therapeutic solutions.

Key Offerings of the Report

• The EMR report gives an overview of the global cancer biomarkers market for the periods (2017-2023) and (2024-2032).

• The report also offers the historical (2017-2023) and forecast (2024-2032) market insights for the type, cancer type, applications, profiling technologies, end users, and regions involved in the market.

• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with an assessment of the SWOT and Porter’s Five Forces models.

The major players in the global cancer biomarkers market are Illumina, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Qiagen N.V., Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Siemens Healthcare Private Limited, PerkinElmer Inc., Bio-Techne, Hologic, Inc., Quest Diagnostics Clinical Laboratories, Inc., and Charles River Laboratories.

Key Highlights of the Report

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over a 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.